July 9, 2007 – Zerusa Limited and Vascular Solutions Announce U.S. Distribution of Guardian Hemostasis Valve

MINNEAPOLIS, Minnesota and GALWAY, Ireland – Zerusa Limited and Vascular Solutions, Inc. (Nasdaq:VASC) today announced that they have entered into a distribution agreement providing for Vascular Solutions to distribute Zerusa’s Guardian¬ hemostasis valve in the United States. The Guardian Hemostasis Valve is designed to maintain hemostasis during interventional catheterization procedures through a novel easy-to-use sealing system which allows simple introduction and removal of interventional devices while providing the option to lock wires in place. The valve is currently sold in Europe through Zerusa’s distribution network and has received 510(k) clearance with the FDA for sales in the United States.

Howard Root, Chief Executive Officer of Vascular Solutions, commented: “This is an excellent addition to our Access Products line, and we are pleased to be able to work with the Zerusa organization on this and hopefully several future product distribution partnerships. We already have performed initial clinical evaluations of the valve with excellent results, and a launch through our 80+ employee direct U.S. sales force is expected following our July national sales meeting.”

Ger Brett, Chief Executive Officer of Zerusa Limited, commented: “This distribution agreement with Vascular Solutions is an important milestone in further developing market acceptance for the innovative Guardian Hemostasis Valve. The combination of our product with Vascular Solutions’ well respected, clinical based direct U.S. sales organization is well-suited to the opportunity.”

About Zerusa Limited

Zerusa Limited designs, develops and markets minimally invasive medical devises for the diagnosis and treatment of vascular disease.

About Vascular Solutions

Vascular Solutions, Inc. is a medical device company that focuses on developing unique solutions for unmet clinical opportunities within interventional radiology and interventional cardiology. The company’s five main product categories consist of hemostat (blood clotting) products, extraction catheters, vein products, specialty catheters and access products. New products introduced since the second half of 2003 include the D-Stat Dry™ hemostatic bandage for the rapid control of topical bleeding, the Pronto™ extraction catheter for the aspiration of soft thrombus, the Langston¬ dual lumen specialty catheter for the measurement of aortic stenosis, the Vari-Lase¬ endovenous laser product line for the treatment of varicose veins, and the Twin-Pass¬ dual access specialty catheter for dual wire access in interventional procedures.

The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2006 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, limited working capital, lack of profitability, exposure to intellectual property claims, dependence on key vendors, exposure to possible product liability claims, the development of new products by others, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, and actions by the FDA.

For further information, connect to www.vascularsolutions.com.

Safe Harbors Statement

This press release contains forward-looking statements. Zerusa Limited wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Zerusa Limited’s overall business strategy, and other factors described in Zerusa Limited’s filings with the United States Securities and Exchange Commission.

Contact: Gerard Brett
Phone Number: +353-91-863061

May 31, 2007 – Zerusa Limited To Attend 2007 Peripheral Course for Revascularization (EuroPCR) in Barcelona, Spain

Zerusa Limited announced today that the Company attended the 2007 EuroPCR Congress for worldwide cardiologists which was held this year in Barcelona, Spain, May 22 ¿ 25, 2007. The Company focused on their innovative Guardian® hemostasis valve which is gaining excellent physician acceptance in the interventional cardiology community. The company’s display was part of the larger Enterprise Ireland exhibit.

About Zerusa Limited

Zerusa Limited designs, develops and markets minimally invasive medical devises for the diagnosis and treatment of vascular disease.

Safe Harbors Statement

This press release contains forward-looking statements. Zerusa Limited wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Zerusa Limited’s overall business strategy, and other factors described in Zerusa Limited’s filings with the United States Securities and Exchange Commission.

Contact: Gerard Brett
Phone Number: +353-91-863061

February 28, 2007 – Zerusa Limited Announces Successful First Year Launch of the Guardian® Hemostasis Valve

Zerusa Limited announced today the Company had a successful first year for the sale of the innovative Guardian® Hemostasis Valve.

Chief Executive Officer, Ger Brett commented, “We are all quite pleased with the introduction of our first product, the Guardian hemostasis valve, into the medical device market. We achieved distribution into many European countries and the United States. In 2007 we look to expand physician acceptance of the technology and distribution in key global markets.”

About Zerusa Limited

Zerusa Limited designs, develops and markets minimally invasive medical devises for the diagnosis and treatment of vascular disease.

Safe Harbors Statement

This press release contains forward-looking statements. Zerusa Limited wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Zerusa Limited’s overall business strategy, and other factors described in Zerusa Limited’s filings with the United States Securities and Exchange Commission.

Contact: Gerard Brett
Phone Number: +353-91-863061

Oct 06

October 18, 2006 – Zerusa Limited to attend the Transcatheter Cardiovascular Therapeutics Meeting in Washington, D.C., U.S.A.

Zerusa Limited and Zerusa North America, LLC announced today that the Company will be attending the 18th the annual Transcatheter Cardiovascular Therapeutics meeting in Washington, D.C., U.S.A., October 23 - 25, 2006.

About Zerusa Limited

Zerusa Limited designs, develops and markets minimally invasive medical devises for the diagnosis and treatment of vascular disease.

Safe Harbors Statement

This press release contains forward-looking statements. Zerusa Limited wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Zerusa Limited’s overall business strategy, and other factors described in Zerusa Limited’s filings with the United States Securities and Exchange Commission.

Contact: Gerard Brett
Phone Number: +353-91-863061

October 4, 2006 – Zerusa Limited Attends Scripps Clinic 17th Annual Coronary Intervention, LaJolla, California

Galway, Ireland, October 5, 2006. Zerusa Limited attended the Scripps Clinic 17th Annual Coronary Interventions 2006 Cardiology Course in LaJolla, California on September 27-39. The course involved education through live case broadcasts and lectures for the audience of medical professionals including cardiologists, nurses and cardiovascular technicians.

Chief Executive Officer, Ger Brett commented, “Coronary Interventions is an outstanding course which offered challenging live cases, insightful lectures and question and answer sessions for the audience. Zerusa gained additional exposure for our innovative Guardian® hemostasis valve. Their were many physicians who visited our booth and expressed interest in trialing the Guardian®. Sales leads were developed from United States West Coast cath labs as well as from many other areas of the country. We look forward to attending Coronary Interventions again next year.”

About Zerusa Limited

Zerusa Limited designs, develops and markets minimally invasive medical devises for the diagnosis and treatment of vascular disease.

Safe Harbors Statement

This press release contains forward-looking statements. Zerusa Limited wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Zerusa Limited’s overall business strategy, and other factors described in Zerusa Limited’s filings with the United States Securities and Exchange Commission.

Contact: Gerard Brett
Phone Number: +353-91-863061

September 15, 2006 – Zerusa Limited Announces United States Registered Trademark for Guardian® Hemostasis Valve

Galway, Ireland, September 15, 2006 - Zerusa Limited announced today that the United States Patent & Trademark Office has notified the company that the Guardian name for it’s hemostasis valve is now a registered trademark of Zerusa Limited. The Company will be incorporate the common symbol ® on all references to the Guardian® in the United States market.

About Zerusa Limited

Zerusa Limited designs, develops and markets minimally invasive medical devises for the diagnosis and treatment of vascular disease.

Safe Harbors Statement

This press release contains forward-looking statements. Zerusa Limited wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Zerusa Limited’s overall business strategy, and other factors described in Zerusa Limited’s filings with the United States Securities and Exchange Commission.

Contact: Gerard Brett
Phone Number: +353-91-863061

May 23, 2006 – Zerusa Limited Attends 2006 Paris Course for Revascularization Congress (EuroPCR)

Galway, Ireland, May 23, 2006 - Zerusa Limited attended the 2006 EuroPCR Congress for worldwide cardiologists. The company exhibited their innovative Guardian® hemostasis valve which is gaining excellent acceptance in the interventional cardiology community. In addition, the company met with numerous physician inventors as integral part of the company’s mission to provide a service to both physician and entrepreneurial inventors assessment of their new product concepts.

About Zerusa Limited

Zerusa Limited designs, develops and markets minimally invasive medical devises for the diagnosis and treatment of vascular disease.

Safe Harbors Statement

This press release contains forward-looking statements. Zerusa Limited wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Zerusa Limited’s overall business strategy, and other factors described in Zerusa Limited’s filings with the United States Securities and Exchange Commission.

Contact: Gerard Brett
Phone Number: +353-91-863061